C/EBP-β-regulated complement hyperactivation in spleen of SFTSV-infected mice: A clue to targeted complement therapy
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1014144 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Yan Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Safe Mining of Deep Coal Resources and Environment Protection, School of Public Health, Anhui University of Science and Tech…. Hauptthemen laut MEDLINE: Spleen, Complement C3, Complement Activation, Phlebovirus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Anhui procince, Scientific Program of Anhui Medical University.
Abstract (Originalsprache)
SFTSV, a tick-borne bunyavirus that causes severe fever with thrombocytopenia syndrome (SFTS), exhibits symptoms such as thrombocytopenia, leukocytopenia, hemorrhage, disseminated intravascular coagulation, and even multiple-organ failure. Nevertheless, the underlying pathogenic pathways of this disease remain poorly understood. In this study, by utilizing a lethal mouse model of IFNAR −/− mice, we discovered that complement hyperactivation occurs in the spleen, and the spleen serves as a source of the central complement component C3 in SFTSV-infected mice. Infection of spleen stromal fibroblastic reticular cells with SFTSV significantly induces intracellular complement pathways through a type I IFN-independent manner and generates the active component C3a through the alternative pathway. The transcription of C3 and complement factor B ( Cfb ) in SFTSV-infected fibroblastic reticular cells is regulated by C/EBP-β. Administration of a C3aR antagonist leads to a reduction in virus load and the inflammatory response, alleviates spleen injury, and prolongs the survival time in IFNAR -/- mice. Collectively, our findings suggest that targeted complement therapy holds potential for the intervention of severe SFTS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Safe Mining of Deep Coal Resources and Environment Protection, School of Public Health, Anhui University of Science and Technology, Huainan, China.
- Department of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
- Anhui Province Key Laboratory of Zoonoses, Anhui Medical University, Hefei, China.
- Department of Traditional Chinese Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Microbiology, Faculty of Naval Medicine, Navy Medical University, Shanghai, China.
- The Second Clinical Medical School, Anhui Medical University, Hefei, China.
ORCID-Profile: Cong Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui procince
- Scientific Program of Anhui Medical University
- Basic - Clinical Collaborative Research Promotion Plan of Anhui Medical University
Zitieren
APA
Liu, Y., Xu, M., Huang, X., Liu, X., Fan, K., Zhang, Y., Xing, C., Tang, H., Jiang, J., Xu, K., He, M., Xu, G., & Zhang, C. (2026). C/EBP-β-regulated complement hyperactivation in spleen of SFTSV-infected mice: A clue to targeted complement therapy. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014144
Vancouver
Liu Y, Xu M, Huang X, Liu X, Fan K, Zhang Y, et al. C/EBP-β-regulated complement hyperactivation in spleen of SFTSV-infected mice: A clue to targeted complement therapy. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014144
BibTeX
@article{Liu2026,
author = {Liu, Yan and Xu, Meng and Huang, Xihua and Liu, Xiaohan and Fan, Kai and Zhang, Yingying and Xing, Chen and Tang, Hailin and Jiang, Jiayue and Xu, Kehan and He, Maozhang and Xu, Gang and Zhang, Cong},
title = {C/EBP-β-regulated complement hyperactivation in spleen of SFTSV-infected mice: A clue to targeted complement therapy},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1014144}
}
EUVIMED